MEDI8897 RSV

A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
To determine if MEDI8897 reduces the amount of visits to see a medical professional due to a lower respiratory tract infection caused by RSV. We will be looking at this in healthy preterm infants entering their first RSV session .
CHLA IRB Number
CHLA-17-00223
Study Type
Clinical Trial
Eligibility
Healthy preterm infants born between 29 weeks 0 days and 34 weeks 6 days
Clinical Trials Government Identifier
NCT02878330
Enrollment Status
Closed
Does this study also recruit healthy volunteers?
No